A citation-based method for searching scientific literature

Hualei Bu, Jingying Chen, Qingshui Li, Jianqing Hou, Yuan Wei, Xiaohang Yang, Yana Ma, Hongsheng He, Youzhong Zhang, Beihua Kong. J Obstet Gynaecol Res 2019
Times Cited: 3

List of co-cited articles
6 articles co-cited >1

Times Cited
  Times     Co-cited

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Nicholas Pulliam, Fang Fang, Ali R Ozes, Jessica Tang, Adeoluwa Adewuyi, Harold Keer, John Lyons, Stephen B Baylin, Daniela Matei, Harikrishna Nakshatri,[...]. Clin Cancer Res 2018

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017

Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.
Maria Teresa Esposito, Lu Zhao, Tsz Kan Fung, Jayant K Rane, Amanda Wilson, Nadine Martin, Jesus Gil, Anskar Y Leung, Alan Ashworth, Chi Wai Eric So. Nat Med 2015

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.
Keith W Pratz, Brian D Koh, Anand G Patel, Karen S Flatten, Weijie Poh, James G Herman, Robert Dilley, Maria I Harrell, B Douglas Smith, Judith E Karp,[...]. Clin Cancer Res 2016

Holliday junction resolution: regulation in space and time.
Joao Matos, Stephen C West. DNA Repair (Amst) 2014

Serine is a new target residue for endogenous ADP-ribosylation on histones.
Orsolya Leidecker, Juan José Bonfiglio, Thomas Colby, Qi Zhang, Ilian Atanassov, Roko Zaja, Luca Palazzo, Anna Stockum, Ivan Ahel, Ivan Matic. Nat Chem Biol 2016

A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
Patricia A Baxter, Jack M Su, Arzu Onar-Thomas, Catherine A Billups, Xiao-Nan Li, Tina Young Poussaint, Edward R Smith, Patrick Thompson, Adekunle Adesina, Pete Ansell,[...]. Neuro Oncol 2020

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.
Yong Fang, Daniel J McGrail, Chaoyang Sun, Marilyne Labrie, Xiaohua Chen, Dong Zhang, Zhenlin Ju, Christopher P Vellano, Yiling Lu, Yongsheng Li,[...]. Cancer Cell 2019

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.
Richard Tuli, Stephen L Shiao, Nicholas Nissen, Mourad Tighiouart, Sungjin Kim, Arsen Osipov, Miranda Bryant, Lindsey Ristow, Veronica Placencio-Hickok, David Hoffman,[...]. EBioMedicine 2019

Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.
Terry J Gaymes, Azim M Mohamedali, Miranda Patterson, Nazia Matto, Alexander Smith, Austin Kulasekararaj, Rajani Chelliah, Nicola Curtin, Farzin Farzaneh, Sydney Shall,[...]. Haematologica 2013

DAMPs, ageing, and cancer: The 'DAMP Hypothesis'.
Jin Huang, Yangchun Xie, Xiaofang Sun, Herbert J Zeh, Rui Kang, Michael T Lotze, Daolin Tang. Ageing Res Rev 2015

Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation.
WooKee Min, Christopher Bruhn, Paulius Grigaravicius, Zhong-Wei Zhou, Fu Li, Anja Krüger, Bénazir Siddeek, Karl-Otto Greulich, Oliver Popp, Chris Meisezahl,[...]. Nat Commun 2013

BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.
Erica L Gornstein, Sara Sandefur, Jon H Chung, Laurie M Gay, Oliver Holmes, Rachel L Erlich, Salil Soman, L Katherine Martin, Andrea V Rose, Philip J Stephens,[...]. Clin Breast Cancer 2018

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Rachel M Hurley, Andrea E Wahner Hendrickson, Daniel W Visscher, Peter Ansell, Maria I Harrell, Jill M Wagner, Vivian Negron, Krista M Goergen, Matthew J Maurer, Ann L Oberg,[...]. Gynecol Oncol 2019

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Junko Murai, Shar-Yin N Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H Doroshow, Yves Pommier. Mol Cancer Ther 2014

Y-box-binding protein 1 as a non-canonical factor of base excision repair.
Elizaveta E Alemasova, Nina A Moor, Konstantin N Naumenko, Mikhail M Kutuzov, Maria V Sukhanova, Pavel E Pestryakov, Olga I Lavrik. Biochim Biophys Acta 2016

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.
Pepijn M Schoonen, Francien Talens, Colin Stok, Ewa Gogola, Anne Margriet Heijink, Peter Bouwman, Floris Foijer, Madalena Tarsounas, Sohvi Blatter, Jos Jonkers,[...]. Nat Commun 2017

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Amit M Oza, Anna V Tinker, Ana Oaknin, Ronnie Shapira-Frommer, Iain A McNeish, Elizabeth M Swisher, Isabelle Ray-Coquard, Katherine Bell-McGuinn, Robert L Coleman, David M O'Malley,[...]. Gynecol Oncol 2017

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016

Mechanisms of resistance to alkylating agents.
G Damia, M D'Incalci. Cytotechnology 1998

The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks.
Ammar A E Ali, Gyula Timinszky, Raquel Arribas-Bosacoma, Marek Kozlowski, Paul O Hassa, Markus Hassler, Andreas G Ladurner, Laurence H Pearl, Antony W Oliver. Nat Struct Mol Biol 2012

High speed of fork progression induces DNA replication stress and genomic instability.
Apolinar Maya-Mendoza, Pavel Moudry, Joanna Maria Merchut-Maya, MyungHee Lee, Robert Strauss, Jiri Bartek. Nature 2018

Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells.
J M de Murcia, C Niedergang, C Trucco, M Ricoul, B Dutrillaux, M Mark, F J Oliver, M Masson, A Dierich, M LeMeur,[...]. Proc Natl Acad Sci U S A 1997

Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1.
Songmin Ying, Freddie C Hamdy, Thomas Helleday. Cancer Res 2012

Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia.
Grazia Palomba, Mario Budroni, Nina Olmeo, Francesco Atzori, Maria Teresa Ionta, Marina Pisano, Francesco Tanda, Antonio Cossu, Giuseppe Palmieri. Oncol Lett 2014

BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies.
Anbok Lee, Byung In Moon, Tae Hyun Kim. Ann Lab Med 2020

RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.
Ahrum Min, Seock-Ah Im, Young-Kwang Yoon, Sang-Hyun Song, Hyun-Jin Nam, Hyung-Seok Hur, Hwang-Phill Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh,[...]. Mol Cancer Ther 2013

Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
Weixin Wang, William D Figg. Cancer Biol Ther 2008

PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.
J Chad Brenner, Felix Y Feng, Sumin Han, Sonam Patel, Siddharth V Goyal, Laura M Bou-Maroun, Meilan Liu, Robert Lonigro, John R Prensner, Scott A Tomlins,[...]. Cancer Res 2012

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Robert L Coleman, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael Friedlander, Aikou Okamoto, Kathleen N Moore, Noa Efrat Ben-Baruch, Theresa L Werner,[...]. N Engl J Med 2019

Purified human BRCA2 stimulates RAD51-mediated recombination.
Ryan B Jensen, Aura Carreira, Stephen C Kowalczykowski. Nature 2010

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu,[...]. N Engl J Med 2015

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Olga Kondrashova, Minh Nguyen, Kristy Shield-Artin, Anna V Tinker, Nelson N H Teng, Maria I Harrell, Michael J Kuiper, Gwo-Yaw Ho, Holly Barker, Maria Jasin,[...]. Cancer Discov 2017

Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.
Céline Montavon, Brian S Gloss, Kristina Warton, Caroline A Barton, Aaron L Statham, James P Scurry, Bruce Tabor, Tuan V Nguyen, Wenja Qu, Goli Samimi,[...]. Gynecol Oncol 2012

Studies on the polymer of adenosine diphosphate ribose. II. Characterization of the polymer.
R H Reeder, K Ueda, T Honjo, Y Nishizuka, O Hayaishi. J Biol Chem 1967

Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Dong Wang, Chengbo Li, Yuan Zhang, Min Wang, Nan Jiang, Lin Xiang, Ting Li, Thomas M Roberts, Jean J Zhao, Hailing Cheng,[...]. Gynecol Oncol 2016

Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase.
Anna E O Fisher, Helfrid Hochegger, Shunichi Takeda, Keith W Caldecott. Mol Cell Biol 2007

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.